TABLE-Brightpath Biotherapeutics -2025/26 parent results

May 14 (Reuters)- Brightpath Biotherapeutics Co., Ltd. PARENT-ONLY FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Mar 31, 2026 Mar 31, 2025 Mar 31, 2027 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 0 mln 1 mln 0 mln (-92.6 pct) Operating loss 1.30 loss 1.16 loss 1.97 Recurring loss 1.29 loss 1.15 loss 1.95 Net loss 1.30 loss 1.15 loss 1.95 EPS loss 11.70 yen loss 14.12 yen loss 13.24 yen Ann Div NIL NIL NIL -Q2 Div NIL NIL NIL -Q4 Div NIL NIL NIL NOTE - Brightpath Biotherapeutics Co., Ltd.. To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4594.T